Catalyst Wire Dossier Catalyst Wire Dossier
EMA approval · 2026-07-10

EMA Authorised: Desloratadine ratiopharm (desloratadine) — Ratiopharm GmbH

View source ↗

Summary

Authorised desloratadine product from Ratiopharm (desloratadine) for allergic rhinitis and urticaria indications in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Desloratadine ratiopharm (desloratadine)

Snippet

Status: Authorised. Therapeutic area: Rhinitis, Allergic, Perennial;Urticaria;Rhinitis, Allergic, Seasonal. MAH: Ratiopharm GmbH. Decision date: 02/07/2026